Clinical

Dataset Information

A randomized phase II trial of adjuvant chemotherapy with UFT/LV versus S-1 following curative resection for stage III colorectal cancer


ABSTRACT: Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days every 5-weeks for 6 months TS-1 80mg per m2 per day for 28 days every 6-weeks for 12 months Primary outcome(s): 3-year disease free survival rate Study Design: Parallel Randomized

DISEASE(S): Stage Iii Colorectal Cancer

PROVIDER: 2617052 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR